Cargando…
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
Chronic plaque psoriasis presents clinically as an inflammatory disease of the skin, which is often associated with comorbidities and responsible for a poor quality of life. It can widely vary among patients because of different age of onset, type of symptoms, areas of involvement, and disease sever...
Autores principales: | Gisondi, Paolo, Girolomoni, Giampiero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887053/ https://www.ncbi.nlm.nih.gov/pubmed/27307707 http://dx.doi.org/10.2147/DDDT.S108115 |
Ejemplares similares
-
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020) -
Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014) -
Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017) -
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020) -
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)